You have 9 free searches left this month | for more free features.

FBXW7 mutation

Showing 26 - 50 of 4,569

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation Trial in Worldwide (BIIB067)

Active, not recruiting
  • ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
  • Phoenix, Arizona
  • +29 more
Sep 2, 2021

Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Trial in Canada (Olaparib, Dasatinib, Nivolumab plus Ipilimumab)

Recruiting
  • Lymphoma, Non-Hodgkin
  • +2 more
  • Edmonton, Alberta, Canada
  • +9 more
Jan 9, 2023

Triple Negative Breast Tumors Trial in Worldwide (alpelisib, , nab-paclitaxel)

Active, not recruiting
  • Triple Negative Breast Neoplasms
  • Los Alamitos, California
  • +154 more
Jan 12, 2023

NSCLC, Colorectal Cancer, Advanced Solid Tumors Trial in Worldwide (GDC-6036, Atezolizumab, Cetuximab)

Recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Duarte, California
  • +68 more
Jan 10, 2023

CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

Completed
  • Chronic Phase Chronic Myelogenous Leukemia
  • +3 more
    • Limerick, Dooradoyle, Ireland
    • +32 more
    Aug 13, 2021

    Cancer Trial in Worldwide (Dabrafenib, Trametinib)

    Completed
    • Cancer
    • Los Angeles, California
    • +49 more
    Apr 1, 2022

    KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma

    Active, not recruiting
    • KRAS Gene Mutation
    • +3 more
    • Sacramento, California
      University of California Davis Comprehensive Cancer Center
    Nov 1, 2021

    Advanced NSCLC, Metastatic NSCLC Trial in Worldwide (MRTX849 Monotherapy, MRTX849 in Combination with Pembrolizumab)

    Recruiting
    • Advanced Non-Small Cell Lung Cancer
    • Metastatic Non-Small Cell Lung Cancer
    • MRTX849 Monotherapy
    • +2 more
    • Prescott Valley, Arizona
    • +134 more
    Jan 25, 2023

    BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma Trial in United States

    Recruiting
    • BRAF V600E Negative
    • +12 more
    • Cetuximab
    • +3 more
    • Scottsdale, Arizona
    • +15 more
    Aug 23, 2022

    Centralized Tumour Board and Secondary Intervention Rate in mCRC

    Not yet recruiting
    • Metastatic Colorectal Cancer
    • +3 more
    • Virtual centralized multidisciplinary tumour board
    • (no location specified)
    Apr 15, 2021

    Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Trial in Worldwide

    Active, not recruiting
    • Acute Myeloid Leukemia (AML)
    • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
    • Los Angeles, California
    • +110 more
    Jan 26, 2023

    Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression = 1% and an STK11

    Recruiting
    • Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
    • Montpellier, France
    • +7 more
    Dec 19, 2022

    Melanoma Trial in Worldwide (Atezolizumab, Atezolizumab Placebo, Cobimetinib)

    Active, not recruiting
    • Melanoma
    • Birmingham, Alabama
    • +115 more
    Jul 11, 2022

    Carotid Plaque Burden in Philadelphia Negative

    Recruiting
    • Myeloproliferative Neoplasm
      • Sohag, Egypt
        Faculty of Medicine
      Aug 14, 2023

      Melanoma Trial in Worldwide (Dabrafenib, Trametinib, Placebos)

      Active, not recruiting
      • Melanoma
      • Birmingham, Alabama
      • +209 more
      Nov 14, 2022

      Advanced or Metastatic Solid Tumor, KRAS G12C Mutation Trial in Changsha (BEBT-607Tablets)

      Recruiting
      • Advanced or Metastatic Solid Tumor
      • KRAS G12C Mutation
      • Changsha, Hunan, China
        Xiangya Hospital of Central South University
      Nov 2, 2023

      Homologous Recombination Repair Pathway Gene Mutation Spectrum

      Not yet recruiting
      • Breast Cancer
        • (no location specified)
        Jun 4, 2023

        NSCLC Trial in Guangzhou (PLB1001)

        Active, not recruiting
        • Non-small Cell Lung Cancer
        • Guangzhou, Guangdong, China
          Guangdong Provincial People's Hospital
        Aug 15, 2023

        Advanced NSCLC Trial in Jinan (almonertinib)

        Recruiting
        • Advanced Non-small Cell Lung Cancer
        • Jinan, Shandong, China
          Degan Lu
        Sep 12, 2023

        Leptin Receptor Deficiency Obesity Trial in Worldwide (setmelanotide, Placebo)

        Completed
        • Leptin Receptor Deficiency Obesity
        • New York, New York
        • +6 more
        Jan 26, 2021

        Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma Trial in

        Active, not recruiting
        • Locally Advanced Pancreatic Adenocarcinoma
        • +4 more
        • Biopsy
        • +4 more
        • Chicago, Illinois
        • +11 more
        Jun 28, 2022

        Lung Cancer Trial in Boston, Nashville

        Active, not recruiting
        • Lung Cancer
          • Boston, Massachusetts
          • +1 more
          Dec 28, 2022

          Cystic Fibrosis, Pulmonary Trial in Shanghai (Sweat Test)

          Recruiting
          • Cystic Fibrosis, Pulmonary
          • Sweat Test
          • Shanghai, Shanghai, China
            Shanghai pulmonary hospital
          Oct 31, 2022

          Non-Small Cell Lung Carcinoma Trial (Capmatinib 150 mg, Capmatinib 200 mg)

          Recruiting
          • Non-Small Cell Lung Carcinoma
          • Capmatinib 150 mg
          • Capmatinib 200 mg
          • Guwahati, Assam, India
          • +7 more
          Dec 19, 2022